<DOC>
	<DOCNO>NCT01442272</DOCNO>
	<brief_summary>The purpose study determine value additional antiproteinuric effect vitamin D derivative treatment , patient Chronic Kidney Illness phase II-IV , lack vitamin D residual proteinuria high 0,5 grams/day .</brief_summary>
	<brief_title>Value Antiproteinuric Effects From Vitamin D Derivatives Patient With Chronic Kidney Illness Lack Vitamin D</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Avitaminosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<criteria>Male/female Patients older 18 year old Patients sign write informed consent Chronic Kidney Illness phase IIIV plus residual proteinuria &gt; 0,5 grams/day ( two consecutive occasion ) plus beta blocker treatment AARS al least 3 month . Serum level calcifediol lack level ( 1530 ng/ml ) . Bad control high blood pressure ( high 180/110 mmHg ) Bad control diabetes ( HbA1c high 9,5 last three month period ) Hypercalcemia ( &lt; 10,2 mg/dL ) hyperphosphatemia ( &gt; 5,5 mg/dL ) , CaxPO4 &gt; 50 , hypercalciuria ( urin Ca/Cr quotient &gt; 0,15 ) Vitamin D treatment analogous Hepatic failure ( AST ALT &gt; 3 time higher normal limit ) medical history poor nutrient intestinal absorption chronic diarrhea Active nephrolithiasis Treatment medication wich change vitamin D metabolism ( phenobarbital , phenytoin , rifampicin ) Participation Clinic Trial 3 last month Active Alcoholism Neoplasia precedent ( except cutaneous melanoma ) Pregnant woman breastfeed Vitamin D hypersensitivity excipient hypersensitivity Any condition Research</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>